Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical Practice: The Get with the Guidelines-Heart Failure (GWTG-HF) Registry

Muthiah Vaduganathan, Stephen J. Greene, Shuaiqi Zhang, Maria Grau-Sepulveda, Adam D. Devore, Javed Butler, Paul A. Heidenreich, Joanna C. Huang, Michelle M. Kittleson, Karen E. Joynt Maddox, James J. McDermott, Anjali Tiku Owens, Pamela N. Peterson, Scott D. Solomon, Orly Vardeny, Clyde W. Yancy, Gregg C. Fonarow*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical Practice: The Get with the Guidelines-Heart Failure (GWTG-HF) Registry'. Together they form a unique fingerprint.

Medicine & Life Sciences